Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gianluca Zaccarello

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Molecular Medicine (Cambridge, Mass.)|April 26, 2013
Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target moleculeAntonella Chillemi, Gianluca Zaccarello, Valeria Quarona, et al.
Oncoimmunology|December 10, 2013
A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytesAlberto L Horenstein, Antonella Chillemi, Gianluca Zaccarello, et al.
Journal of Molecular Endocrinology|July 28, 2010
The hidden life of NAD+-consuming ectoenzymes in the endocrine systemFabio Malavasi, Silvia Deaglio, Gianluca Zaccarello, et al.
Cytometry. Part B, Clinical Cytometry|April 12, 2013
CD38 and CD157: a long journey from activation markers to multifunctional moleculesValeria Quarona, Gianluca Zaccarello, Antonella Chillemi, et al.
Frontiers in Bioscience (Landmark Edition)|January 7, 2014
CD38 and bone marrow microenvironmentAntonella Chillemi, Gianluca Zaccarello, Valeria Quarona, et al.
The American Journal of Dermatopathology|March 26, 2009
A high percentage of skin melanoma cells expresses SPANX proteinsMichele Salemi, Aldo E Calogero, Enzo Vicari, et al.
Oncotarget|September 3, 2015
A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferationFabio Morandi, Barbara Morandi, Alberto L Horenstein, et al.
Breast Cancer Research and Treatment|December 15, 2010
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenibGiorgio Valabrega, Sonia Capellero, Giuliana Cavalloni, et al.
Annals of the New York Academy of Sciences|July 23, 2014
Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow nicheValeria Quarona, Valentina Ferri, Antonella Chillemi, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Molecular Medicine (Cambridge, Mass.)|April 26, 2013
Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target moleculeAntonella Chillemi, Gianluca Zaccarello, Valeria Quarona, et al.
Oncoimmunology|December 10, 2013
A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytesAlberto L Horenstein, Antonella Chillemi, Gianluca Zaccarello, et al.
Journal of Molecular Endocrinology|July 28, 2010
The hidden life of NAD+-consuming ectoenzymes in the endocrine systemFabio Malavasi, Silvia Deaglio, Gianluca Zaccarello, et al.
Cytometry. Part B, Clinical Cytometry|April 12, 2013
CD38 and CD157: a long journey from activation markers to multifunctional moleculesValeria Quarona, Gianluca Zaccarello, Antonella Chillemi, et al.
Frontiers in Bioscience (Landmark Edition)|January 7, 2014
CD38 and bone marrow microenvironmentAntonella Chillemi, Gianluca Zaccarello, Valeria Quarona, et al.
The American Journal of Dermatopathology|March 26, 2009
A high percentage of skin melanoma cells expresses SPANX proteinsMichele Salemi, Aldo E Calogero, Enzo Vicari, et al.
Oncotarget|September 3, 2015
A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferationFabio Morandi, Barbara Morandi, Alberto L Horenstein, et al.
Breast Cancer Research and Treatment|December 15, 2010
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenibGiorgio Valabrega, Sonia Capellero, Giuliana Cavalloni, et al.
Annals of the New York Academy of Sciences|July 23, 2014
Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow nicheValeria Quarona, Valentina Ferri, Antonella Chillemi, et al.
Pageof 1